Ocugen (OCGN) Share-based Compensation (QoQ) (2014 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Ocugen | 452.01 Mn | 452.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 69.73% |
| Dec 31, 2025 | 1.32% |
| Sep 30, 2025 | 166.67% |
| Jun 30, 2025 | -60.69% |
| Mar 31, 2025 | 0.48% |
| Dec 31, 2024 | -0.85% |
| Sep 30, 2024 | -0.32% |
| Jun 30, 2024 | 7.78% |
| Mar 31, 2024 | 2.26% |
| Dec 31, 2023 | -20.79% |
| Sep 30, 2023 | -17.40% |
| Jun 30, 2023 | -2.12% |
| Mar 31, 2023 | 0.79% |
| Dec 31, 2022 | 6.93% |
| Sep 30, 2022 | 20.01% |
| Jun 30, 2022 | -36.98% |
| Mar 31, 2022 | 22.96% |
| Dec 31, 2021 | 99.18% |
| Sep 30, 2021 | -35.70% |
| Jun 30, 2021 | 151.50% |
| Mar 31, 2021 | 411.04% |
| Dec 31, 2020 | 29.37% |
| Sep 30, 2020 | -15.44% |
| Jun 30, 2020 | -32.88% |
| Mar 31, 2020 | 35.38% |
| Dec 31, 2019 | -15.04% |
| Sep 30, 2019 | 72.62% |
| Jun 30, 2019 | -73.07% |
| Mar 31, 2019 | 26.35% |
| Dec 31, 2018 | -24.98% |
| Sep 30, 2018 | 7.35% |
| Jun 30, 2018 | 1.24% |
| Mar 31, 2018 | 18.53% |
| Dec 31, 2017 | -7.86% |
| Sep 30, 2017 | -0.54% |
| Jun 30, 2017 | -24.59% |
| Mar 31, 2017 | 5.13% |
| Dec 31, 2016 | 7.59% |
| Sep 30, 2016 | 29.46% |
| Jun 30, 2016 | 8.04% |
| Mar 31, 2016 | -16.84% |
| Dec 31, 2015 | 3.31% |
| Sep 30, 2015 | 40.86% |
| Jun 30, 2015 | 9.36% |
| Mar 31, 2015 | 23.04% |
| Dec 31, 2014 | 13.69% |
| Sep 30, 2014 | 50.00% |
| Jun 30, 2014 | 47.37% |